Phase-II study of Navelbine in advanced breast cancer.
Canobbio
L
L
National Institute for Cancer Research, Genoa, Italy.
Boccardo
F
F
Pastorino
G
G
Brema
F
F
Martini
C
C
Resasco
M
M
Santi
L
L
D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D003248:Constipation / Q000139:chemically induced; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008113:Liver Neoplasms / Q000188:drug therapy / Q000556:secondary; D008175:Lung Neoplasms / Q000188:drug therapy / Q000556:secondary; D008207:Lymphatic Metastasis; D008875:Middle Aged; D010292:Paresthesia / Q000139:chemically induced; D012074:Remission Induction; D012878:Skin Neoplasms / Q000188:drug therapy / Q000556:secondary; D014747:Vinblastine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000077235:Vinorelbine
D000970:Antineoplastic Agents; D014747:Vinblastine; D000077235:Vinorelbine